| Name | Title | Contact Details |
|---|
Battle Creek Health System (BCHS) is a multi-campus health care provider serving approximately 200,000 people in south central Michigan. BCHS was formed through the merger of Battle Creek's two acute care hospitals-Leila Y. Post Montgomery Hospital and
Memorial Hospital at Gulfport is a not-for-profit medical complex in Gulfport, Mississippi, jointly owned by the City of Gulfport and Harrison County. Memorial is one of the most comprehensive healthcare systems in the state, licensed for 303 beds, including a state-designated Level II Trauma Center, two outpatient surgery centers, satellite outpatient diagnostic and rehabilitation centers and more than 95 Memorial Physician Clinics. Memorial offers several of the region`s most comprehensive clinical programs, such as emergency medicine; women and children services; orthopedic services; cardiovascular services; neurosciences and oncology. Additionally, Memorial provides medical specialties unique to the coast which include a Level III Neonatal ICU and Mississippi`s first nationally certified Primary Stroke Center. Memorial offers 3D imaging and advanced surgical techniques, including the robotic assisted Specialty Surgery System. Memorial is accredited by The Joint Commission, the Commission on Cancer, the College of American Pathologists and the American College of Radiology.
Preferred Healthcare System (PHS) works through insurers and third-party administrators to provide a network of hospitals, physicians, and ancillary providers who can deliver a broad scope of healthcare services. PHS provides this network of hospitals
Santo Remedio is a Hispanic health and wellness startup that creates supplements and communities focused on preventative solutions to health problems, tailored to individual needs.
Ritter Pharmaceuticals, Inc. is a specialty pharmaceutical company developing therapeutics based upon colonic adaptation to treat gastrointestinal diseases with an initial focus on lactose intolerance. Colonic adaptation improves colon function by selectively increasing the growth of beneficial bacteria in the colonic ecosystem (digestive tract). Ritter Pharmaceuticals, Inc. is rapidly establishing itself as the world`s leader in lactose intolerance research based upon its scientific team and their cutting edge research in this field. RP-G28, Ritter`s lead product, has been studied in a Phase 2 trial and is a first-in-class compound. RP-G28 has the potential to become the first FDA-approved drug for the treatment of lactose intolerance, a debilitating disease which affects over 1 billion people worldwide.